ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1554-1562

  Vilmar, Adam ^a   Santoni Rugiu, Eric ^b   Sørensen, Jens Benn ^a  

^a FINSEN LABORATORY   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Advanced NSCLC; ERCC1; Histopathology; Predictive biomarkers; Toxicity and quality of life

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77952585994     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.045     Document Type: Article

References (30)

1. Ardizzoni A., Boni L., Tiseo M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 11 (2007) 847-857
2. Zhu C.Q., da Cunha S.G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26 26 (2008) 4268-4275
3. Scagliotti G.V., Parikh P., von P.J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 21 (2008) 3543-3551
4. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 19 (2007) 2747-2754
5. de Laat W.L., Jaspers N.G., and Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev 13 7 (1999) 768-785
6. Wijnhoven S.W., Hoogervorst E.M., de W.H., van der Horst G.T., and van S.H. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models. Mutat Res 614 1-2 (2007) 77-94
7. Cummings M., Higginbottom K., McGurk C.J., et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72 2 (2006) 166-175
8. Azuma K., Komohara Y., Sasada T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98 9 (2007) 1336-1343
9. Holm B., Mellemgaard A., Skov T., and Skov B.G. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27 26 (2009) 4254-4259
10. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl J Med 355 10 (2006) 983-991
11. Wang X., Zhao J., Yang L., et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol June 2 (2009)
12. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., and Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2 10 (2007) 902-906
13. Isla D., Sarries C., Rosell R., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15 8 (2004) 1194-1203
14. Chua W., Goldstein D., Lee C.K., et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Brit J Cancer 101 6 (2009) 998-1004
15. Khrunin A.V., Moisseev A., Gorbunova V., and Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenom J 10 1 (2010) 54-61
16. Kim H.S., Kim M.K., Chung H.H., et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113 2 (2009) 264-269
17. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., and Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25 29 (2007) 4528-4535
18. Sorensen J.B., Hansen O., Vilmar A.C., and Frank H. Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer. J Clin Oncol 27 (2009) 15s [suppl; abstr 8034]
19. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in 443 advanced NSCLC patients randomized in a multicenter phase III trial. Ann of Oncol Advance Access March 23, 2010.
20. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 5 (1993) 365-376
21. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., and Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A 5 (1994) 635-642
22. King M.T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5 6 (1996) 555-567
23. Darcy K.M., Tian C., and Reed E. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67 9 (2007) 4474-4481
24. Smith S., Su D., Rigault de la Longrais I.A., et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25 33 (2007) 5172-5179
25. Kwon H.C., Roh M.S., Oh S.Y., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 3 (2007) 504-509
26. Ruzzo A., Graziano F., Loupakis F., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 10 (2007) 1247-1254
27. Tibaldi C., Giovannetti E., Vasile E., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14 6 (2008) 1797-1803
28. Suk R., Gurubhagavatula S., Park S., et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11 4 (2005) 1534-1538
29. Di M.M., Gridelli C., Gallo C., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6 9 (2005) 669-677
30. Cameron D.A., Massie C., Kerr G., and Leonard R.C. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Brit J Cancer 89 10 (2003) 1837-1842